These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23280652)

  • 1. Evaluation of FDA safety-related drug label changes in 2010.
    Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
    Shimazawa R; Ikeda M
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 5. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 6. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 7. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 8. European Medicines Agency assesses safety reporting at Roche.
    Marshall H
    Lancet Oncol; 2012 Aug; 13(8):e331. PubMed ID: 23024993
    [No Abstract]   [Full Text] [Related]  

  • 9. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L; Zalkikar J; Tiwari RC
    J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
    Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US FDA patient-reported outcome guidance: great expectations and unintended consequences.
    Fehnel S; DeMuro C; McLeod L; Coon C; Gnanasakthy A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):441-6. PubMed ID: 23977972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.